PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Rating)’s stock price was up 7.2% during mid-day trading on Wednesday . The company traded as high as $37.62 and last traded at $36.86. Approximately 3,948 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 333,271 shares. The stock had previously closed at $34.37.
A number of analysts have recently issued reports on PRCT shares. Guggenheim lowered their price target on PROCEPT BioRobotics from $55.00 to $40.00 in a research note on Wednesday, March 9th. SVB Leerink lifted their price objective on PROCEPT BioRobotics from $25.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 9th. Finally, Bank of America reduced their price objective on PROCEPT BioRobotics from $48.00 to $42.00 and set a “buy” rating on the stock in a research report on Wednesday, March 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $39.80.
The company has a quick ratio of 20.01, a current ratio of 20.87 and a debt-to-equity ratio of 0.20. The stock has a 50-day simple moving average of $36.88 and a 200 day simple moving average of $29.65.
PROCEPT BioRobotics (NASDAQ:PRCT – Get Rating) last posted its earnings results on Thursday, May 5th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.08. The business had revenue of $14.20 million during the quarter, compared to analysts’ expectations of $12.10 million. As a group, equities research analysts expect that PROCEPT BioRobotics Co. will post -1.86 EPS for the current fiscal year.
In other PROCEPT BioRobotics news, major shareholder Global Investors Lp Viking sold 1,249,000 shares of PROCEPT BioRobotics stock in a transaction on Friday, March 18th. The stock was sold at an average price of $29.90, for a total value of $37,345,100.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
Several hedge funds have recently bought and sold shares of PRCT. BlackRock Inc. purchased a new stake in shares of PROCEPT BioRobotics in the 3rd quarter valued at $763,000. Goldman Sachs Group Inc. purchased a new stake in shares of PROCEPT BioRobotics in the 3rd quarter valued at $2,205,000. Geode Capital Management LLC purchased a new stake in shares of PROCEPT BioRobotics in the 3rd quarter valued at $352,000. Johnson & Johnson purchased a new stake in shares of PROCEPT BioRobotics in the 3rd quarter valued at $38,855,000. Finally, Balyasny Asset Management LLC purchased a new stake in shares of PROCEPT BioRobotics in the 3rd quarter valued at $1,120,000. Hedge funds and other institutional investors own 65.72% of the company’s stock.
About PROCEPT BioRobotics (NASDAQ:PRCT)
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Receive News & Ratings for PROCEPT BioRobotics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PROCEPT BioRobotics and related companies with MarketBeat.com’s FREE daily email newsletter.